Company intelligence / Profile preview

Civitas Therapeutics

Chelsea, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Civitas Therapeutics demonstrated positive Phase 2 and Phase 2b results with CVT-301 (inhaled levodopa) showing rapid and durable improvement for "OFF" episodes in Parkinson’s disease; safety and tolerability were favorable compared to oral standards and pivotal Phase 3 was planned prior to acquisition[4][13].

Therapeutic areas: Neurology
Modalities: Small moleculeDevice
Industry: Biotech

Partnerships

The Michael J. Fox Foundation for Parkinson’s Research (clinical funding support)

Beyond the preview

Go deeper on Civitas Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Civitas Therapeutics.

Explore the full profile